IDEAYA Biosciences' Upcoming Investor Engagements
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a dedicated precision medicine oncology company known for its innovative work in targeted therapeutics, is set to participate in significant investor relations events. With a focus on advancing cancer treatment, IDEAYA’s participation in these events highlights its commitment to transparency and engagement with investors.
Details of the Investor Events
The firm will be involved in two notable engagements this fall, allowing stakeholders to gain valuable insights into ongoing projects and the company's vision.
Citi's 2025 SMID Cap Biopharma Call Series
This event is scheduled for Thursday, November 6, 2025, at 12:00 PM ET. During this invitation-only forum, Yujiro S. Hata, President and Chief Executive Officer of IDEAYA, will engage in a fireside chat. He will be hosted by Yigal D. Nochomovitz, Ph.D., who serves as the Director for SMid Cap Biotech Analysts.
Jefferies Global Healthcare Conference in London
The second event will take place on Tuesday, November 18, 2025, at 1:00 PM GMT / 8:00 AM ET. This conference will also feature Yujiro S. Hata in a fireside chat, facilitated by Maury Raycroft, Ph.D., an Equity Research Analyst specializing in Biotechnology.
Accessing Live Coverage of the Events
For those interested in following along, a live audio webcast of both engagements will be available in the 'Investors/Events' section of the IDEAYA website. Replays of the webcasts will also be accessible for a period of 30 days after each event concludes, providing an opportunity for those unable to attend live to catch up on the discussions.
About IDEAYA Biosciences
IDEAYA Biosciences is revolutionizing cancer treatment through precision medicine. The company is dedicated to discovering, developing, and commercializing transformative therapies. By fusing small-molecule drug discovery with in-depth structural biology and bioinformatics, IDEAYA is equipped to pioneer targeted therapies that address the unique genetic drivers of various cancers.
With a robust pipeline focused on synthetic lethality and antibody-drug conjugates (ADCs), IDEAYA aims to redefine the landscape of oncology treatments, ensuring they are more personalized and effective. The mission is clear: to change the trajectory of cancer therapy and improve outcomes for patients, making every treatment as effective as possible.
Frequently Asked Questions
What is IDEAYA Biosciences focused on?
IDEAYA Biosciences primarily focuses on the discovery and development of targeted therapeutics in the field of precision medicine for cancer treatment.
When are the upcoming investor events?
The upcoming investor events are scheduled for November 6 and November 18, 2025.
Who will represent IDEAYA at these events?
Yujiro S. Hata, the President and Chief Executive Officer, will represent IDEAYA at both investor events.
Will there be live coverage of the events?
Yes, a live audio webcast of each event will be available on the IDEAYA website.
How long will the webcast replays be available?
Replays of the webcasts will be accessible for 30 days following each live event.
